Ibrutinib Yields Response in Patients With Chronic GVHD

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video examines a phase I/II study of ibrutinib in patients with chronic GVHD who failed corticosteroids.

Lori Styles, MD, on Ibrutinib in Chronic GVHD
Current Time 0:00
Duration 4:36
Loaded: 3.55%
Stream Type LIVE
Remaining Time 4:36
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Chronic graft vs host disease (GVHD) is a serious complication of allogeneic stem cell transplantation, and among patients who fail corticosteroids there remains an unmet need for an effective therapy.

    In this video, Lori Styles, MD, medical director of Pharmacyclics in Sunnyvale, California, discusses a phase I/II study of ibrutinib in patients with chronic GVHD who failed corticosteroids.

    Results of the trial (abstract LBA-3) were presented at the 58th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.

    Recent Videos
    Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
    Spreading Greater CAR T-Cell Therapy Education in the Community Setting
    Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
    Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
    Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
    Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
    A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
    Hybrid Model of CAR T-Cell Therapy May Help Manage Treatment-Related Infections
    A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
    Secondary Malignancies Risk Still in Question Following CAR T-cell Therapy for Lymphoma
    A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
    Study Aims to Address CAR T Accessibility Among Disadvantaged Groups
    Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
    Addressing Challenges in TP53-Mutant Acute Myeloid Leukemia
    Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
    Menin Inhibitor Developments Move Acute Myeloid Leukemia Landscape Forward
    Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
    Advocate Outlines Resources for Chronic Myeloid Leukemia Population
    Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
    Expert Highlights Risk Factors for Disease Progression in Polycythemia Vera
    Related Content
    An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

    Blinatumomab-Related ICANS Symptoms More Prevalent Than Prior Reports

    Russ Conroy
    April 11th 2025
    Article

    An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

    A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

    Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

    Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
    October 21st 2024
    Podcast

    A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

    Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

    Orca-T Displays cGVHD-Free Survival Benefit in Hematologic Malignancies

    Roman Fabbricatore
    March 17th 2025
    Article

    Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

    Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

    Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

    Rahul Banerjee, MD, FACP;Noopur Raje, MD
    September 2nd 2024
    Podcast

    Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

    BMT CTN 1902: Post-transplant Consolidation is Back, and This Time With CAR-T!

    BMT CTN 1902: Post-transplant Consolidation is Back, and This Time With CAR-T!

    American Society for Transplantation and Cellular Therapy
    March 3rd 2025
    Article

    Overall, BMT CTN 0702 showed no improvement in outcomes with added post-ASCT consolidation as compared to standard lenalidomide maintenance.

    Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

    Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

    Russ Conroy
    February 14th 2025
    Article

    Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.